Aspen Pharmacare Stock Stands Out As South Africa Tariff Exemptions Reshape Trade Picks

New US tariffs on dozens of countries have put South Africa back in the global trade spotlight, yet several key exports are untouched and trade with BRICS partners is growing. That combination of pressure and protection can reshuffle which stocks face challenges and which show resilience. This article examines three South Africa Trade Tariffs Impact Stocks Opportunities picks, two potential winners and one potential loser, to help you decide where to pay closer attention now.

Aspen Pharmacare Holdings (JSE:APN)

Aspen Pharmacare Holdings manufactures and markets branded and specialty medicines, including injectables, over the counter products and prescription drugs, as well as active pharmaceutical ingredients and other finished dose forms across multiple regions. Revenue is fairly evenly spread across its Commercial Pharmaceuticals segments, with injectables at about ZAR 10.2b, OTC at ZAR 10.0b and prescription products at ZAR 12.5b, alongside a ZAR 9.8b manufacturing arm. Aspen Pharmacare Holdings has a market cap of roughly ZAR 65.6b.

Investors watching tariff headlines may find Aspen Pharmacare Holdings interesting because it sits in a specific niche. Its pharmaceutical exports are explicitly exempt from the new US tariffs, and it is leaning into BRICS and Global South demand at the same time as insulin and GLP 1 manufacturing ramps up. The company is still working through losses and funding risk, and some forecasts suggest revenue may soften even as earnings expectations indicate a potential recovery. The share price is below some fair value estimates, which can appeal to value focused investors, but the key issue is whether execution on new contracts and capacity ultimately supports closing that gap.

Aspen Pharmacare Holdings looks like a valuation story that many investors have only half finished. The share price, fair value debate and tariff shield all meet in the analysis report for Aspen Pharmacare Holdings and the one issue that could flip the script.

Build your own tariff shield shortlist

Aspen Pharmacare Holdings and the other South Africa Trade Tariffs Impact Stocks Opportunities in this article all surfaced from a single screener, but the real edge comes when you set the rules yourself. Use our flexible Screener to combine valuation, future growth and risk filters that fit your style, or start with any of our curated Investing Ideas.

Sappi (JSE:SAP)

Sappi is a global producer of woodfiber based renewable materials, ranging from specialty and packaging papers to dissolving pulp and biomaterials, with operations across Europe, North America and South Africa. Revenue is concentrated in Europe at about US$2.4b, followed by North America at roughly US$1.7b and South Africa at about US$1.5b, after segment adjustments. The company has a market cap of roughly ZAR 7.6b.

Investors watching tariff headlines may view Sappi as a high risk turnaround story that now faces an extra headwind. The company is already dealing with weak paper margins, rising net debt and reported losses of US$181 million in Q3 and US$631 million over the nine months to June 2026, while export exposed products may be caught in new US tariff friction. At the same time, management is trying to shift toward higher value packaging, execute a complex European joint venture and manage sharp currency swings that squeeze South African profits. Anyone evaluating Sappi’s low P/S and renewable materials profile needs to weigh whether this mix of leverage, US trade pressure and execution risk represents a contrarian opportunity or a potential value trap.

Sappi’s weak paper margins, rising net debt and US tariff risk could be masking a deeper balance sheet story that many investors have not fully joined the dots on yet. Before assuming this is just a cheap renewable materials play, read the Sappi financial health report

Impala Platinum Holdings (JSE:IMP)

Impala Platinum Holdings is one of the world’s key suppliers of platinum group metals, mining and refining platinum, palladium, rhodium and associated base metals across South Africa, Zimbabwe and Canada. Revenue is driven mainly by Mining Impala at about ZAR 40.9b and Impala Refining Services at roughly ZAR 46.0b, with additional contributions from Zimplats at about ZAR 19.8b, Impala Canada at roughly ZAR 5.6b and Marula at about ZAR 5.2b. The company has a market cap of around ZAR 181.8b.

Impala Platinum Holdings sits at the crossroads of two powerful forces. On one side, PGMs are exempt from the latest US tariffs and management describes these metals as critical to global industries, which supports interest in long term supply agreements and security of supply. On the other side, the company is priced for strong earnings growth, yet faces higher funding risk, safety setbacks such as the Rustenburg reset in July 2026 and long term questions over PGM demand as electric vehicles gain share. For investors weighing high quality earnings, experienced leadership and tariff protection against valuation and structural demand risk, Impala Platinum is a trade sensitive stock that may warrant closer attention.

Impala Platinum’s tariff shield and critical metals story look powerful, yet the real twist may sit in the growth expectations already baked into the stock. Before assuming the upside is obvious, review the analyst forecasts for Impala Platinum Holdings

Seeking Fresh Alternatives Beyond Tariff Trades

Shortlists move fast. Breakout themes, early momentum and falling laggards can get caught by the crowd before the best entry points vanish. Scan fresh ideas now and act early.

• Spot fresh momentum in companies with strong balance sheets before they stop flying under the radar using our curated list of solid balance sheet and fundamentals (422 results).
• Target potential cash generating machines as income ideas start gaining attention, with a focused view across our curated 442 dividend fortresses.
• Ride long term metal demand themes while they are still under the radar for now by scanning our hand picked 8 top copper producer stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com